Bio-Rad Laboratories is a renowned company in the life science and clinical diagnostics sectors, offering a comprehensive portfolio of cutting-edge products and solutions. Their product line includes molecular biology reagents, cell culture products, and imaging systems for drug discovery and life science research. Bio-Rad also caters to clinical laboratories and blood banks, providing diagnostic testing equipment and consumables.
The company's decision to delist from the New York Stock Exchange (NYSE) and transfer its listing to the Tel Aviv Stock Exchange (TASE) in Israel was the primary reason for its removal from the S&P 500 index in 2024. This move was part of Bio-Rad's strategy to streamline its corporate structure and reduce costs associated with dual-listing on both US and Israeli exchanges. Additionally, the company's market capitalization fell below the minimum threshold required for inclusion in the S&P 500 index.